UNSPSC 51112804: Raloxifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C28H27NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX9162EO3I, chemically known as methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)- but more generally known as raloxifene, which bears US NIH Compound Identifier 5035. European Medicines Agency schedules Raloxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10243MIG.

UNSPSC 51112804 Raloxifene is a Commodity code for a selective estrogen receptor modulator (SERM) pharmaceutical used primarily in the treatment and prevention of osteoporosis in postmenopausal women. State and local governments procure raloxifene through their pharmacy benefit management programs, Medicaid formularies, and public health clinics to serve eligible populations including low-income beneficiaries, seniors, and individuals with diagnosed bone-density disorders. The drug is typically purchased as a generic formulation in tablet form, often through state pharmaceutical bulk-purchasing arrangements or cooperative purchasing agreements that leverage volume discounts. Issuing bodies acquiring raloxifene span state health and human services departments (which manage Medicaid pharmacy benefits), county health departments and public hospitals, municipal public health clinics, and independent school districts that maintain student health services. Prison and corrections systems also procure the drug for inmate populations.

The source provided contains no recent state or local contract opportunities tagged to UNSPSC 51112804. Without posted solicitations, RFQs, or RFPs identifying raloxifene procurement activity, geographic concentration and representative recent opportunities cannot be characterized from current market signals.